GEn1E Lifesciences Inc. Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

GEn1E Lifesciences is a clinical-stage biotechnology company based in Palo Alto, California, with a laboratory in Mountain View, focused on developing precision therapies for immunology, inflammatory and rare diseases. It aims to accelerate the discovery and development of first-in-class kinase modulators using artificial intelligence, and its differentiated mechanism of action for these compounds has been published in the Journal of Pharmacology and Experimental Therapeutics. The company is led by founder and CEO Dr. Ritu Lal, who has three FDA approvals in the United States and Japan.
GEn1E Lifesciences is advancing four products in its portfolio, including a lead compound that moved from early discovery to Phase 2 in about 2.5 years, and it holds FDA Fast Track designation as well as a collaboration with BARDA to apply AI-driven endotyping in clinical studies. Its development approach is described as Platform-in-a-Mechanism, and three additional drug candidates are in progress, with two oral therapies for chronic diseases nearing Phase 1 and a fourth candidate targeting pancreatic cancer. In December 2024, François Nader, MD, was appointed chair of the board.

Get verified GEn1E Lifesciences Inc. emails free

Company overview Employee directory